Last $10.86 USD
Change Today +0.23 / 2.16%
Volume 674.9K
MNTA On Other Exchanges
As of 8:10 PM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).

momenta pharmaceuticals inc (MNTA) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/28/14 - $19.16
52 Week Low
10/13/14 - $9.38
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

momenta pharmaceuticals inc (MNTA) Related Businessweek News

No Related Businessweek News Found

momenta pharmaceuticals inc (MNTA) Details

Momenta Pharmaceuticals, Inc., a biotechnology company, is engaged in the structural characterization, process engineering, and biologic systems analysis of complex molecules in the areas of complex generics, biosimilars, and novel drugs. The company’s complex generics programs comprise Enoxaparin sodium injection, a generic version of Lovenox that is used for the prevention and treatment of deep vein thrombosis, and to support the treatment of acute coronary syndromes; and M356, a generic version of Copaxone, which is a glatiramer acetate injection indicated for the reduction of the frequency of relapses in patients with relapsing-remitting multiple sclerosis. Its biosimilars programs include M923 and M834, which are biosimilars for autoimmune and inflammatory diseases; and M511, a monoclonal antibody for oncology. The company’s novel products comprise M402, a novel oncology drug candidate that is in a Phase 1/2 clinical study, which binds to various growth factors, adhesion molecules, and chemokines to inhibit tumor progression, metastasis, and angiogenesis; and the sialylation technology that is a discovery program of a mixture of human immunoglobulin G antibodies for the treatment of inflammatory diseases. It has collaboration and license agreements with Sandoz AG; Baxter International, Inc.; Baxter Healthcare Corporation; and Baxter Healthcare SA. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is based in Cambridge, Massachusetts.

269 Employees
Last Reported Date: 02/28/14
Founded in 2001

momenta pharmaceuticals inc (MNTA) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $621.0K
Co-Founder, Chief Scientific Officer and Seni...
Total Annual Compensation: $387.5K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $362.5K
Senior Vice President and President of Biosim...
Total Annual Compensation: $19.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $395.7K
Compensation as of Fiscal Year 2013.

momenta pharmaceuticals inc (MNTA) Key Developments

Momenta Pharmaceuticals Inc. Adopts Third Amended and Restated By-Laws

On December 10, 2014, the Board adopted the Third Amended and Restated By-laws of Momenta Pharmaceuticals Inc. The By-laws became effective immediately upon adoption by the Board, and include the following amendment. A new Article VI (Article VI) has been added to the By-laws to provide that, unless the Company consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (the Court of Chancery) (or, if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware) will be the sole and exclusive forum for the following actions: (i) any derivative action or proceeding brought on behalf of the Company; (ii) any action asserting a claim for breach of a fiduciary duty owed by, or other wrongdoing by, any director, officer or other employee or agent of the Company to the Company or the Company's stockholders, creditors or other constituents; (iii) any action arising pursuant to any provision of the Delaware General Corporation Law or the Company's certificate of incorporation or by-laws; (iv) any action to interpret, apply, enforce or determine the validity of the Company's certificate of incorporation or by-laws; and (v) any action asserting a claim against the Company governed by the internal affairs doctrine. Pursuant to Article VI, to the fullest extent permitted by applicable law, any person or entity purchasing or otherwise acquiring any interest in shares of capital stock of the Company shall be deemed to have notice of and consented to the provisions of Article VI. Article VI further provides that, if any provision or provisions of Article VI are held to be invalid, illegal or unenforceable as applied to any person or entity or circumstance, then, to the fullest extent permitted by law, the validity, legality and enforceability of such provisions in any other circumstance and of the remaining provisions of Article VI will not be affected.

Peter Barton Hutt to Retire from Momenta Pharmaceuticals Inc.'s Board of Directors, Effective December 31, 2014

Peter Barton Hutt notified Momenta Pharmaceuticals Inc. that he will retire from the company's Board of Directors, effective December 31, 2014. Mr. Hutt has served as a director since June 2001 and currently serves as member of the Nominating and Corporate Governance Committee. Mr. Hutt's retirement was not the result of any disagreement with the company on any matter relating to the company's operations, policies or practices.

Momenta Pharmaceuticals Inc. Presents at Stifel Healthcare Conference 2014, Nov-19-2014 08:35 AM

Momenta Pharmaceuticals Inc. Presents at Stifel Healthcare Conference 2014, Nov-19-2014 08:35 AM. Venue: The Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Richard P. Shea, Chief Financial Officer, Principal Accounting Officer, Senior Vice President and Treasurer.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MNTA:US $10.86 USD +0.23

MNTA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Natco Pharma Ltd 1,369 INR +6.55
OraSure Technologies Inc $10.03 USD +0.16
Pernix Therapeutics Holdings Inc $8.87 USD +0.19
SciClone Pharmaceuticals Inc $7.37 USD -0.04
Sucampo Pharmaceuticals Inc $15.99 USD +0.81
View Industry Companies

Industry Analysis


Industry Average

Valuation MNTA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.5x
Price/Book 2.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MOMENTA PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at